76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 56-57

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Background/Significance

Surgical navigation and localization advancements seek to improve surgical time, total tissue excised, and the need for
re-excision in breast surgery. Bracketed localization is frequently used for procedures localizing wide or multifocal breast tumors. Electromagnetic chip (EMC) localization via Smart Clip (Elucent Medical, Madison WI) is a novel approach to clip localization. This prospective evaluation compares EMC bracketed localization to conventional wire localization in bracketed breast conserving surgery (BCS).

Materials and Methods

A prospective, institutional review board–approved single-institution cohort of female patients with breast cancer undergoing EMC bracketed localization was compared with a contemporary cohort of patients with breast cancer undergoing wire bracketed BCS. Key variables included number of localizers placed, complete retrieval of localizers, additional margins taken intraoperatively, positive malignant margins, reoperation for positive margins, time of incision to radiograph, and specimen length (mm) and volume (cm3). Statistics were performed using Kruskal-Wallis test for numerical covariates and χ2 test or Fisher exact test, where applicable, for categorical covariates.

Results

Seventy-four subjects were included, 31 with EMC localization vs 43 wire localization; of these, 10 EMC and 4 wire localized cases were oncoplastic reductions. All cases were performed by 8 fellowship-trained breast surgeons. The mean age was 66 years (range, 36-86). Mean tumor size was 41.2 mm for EMC vs 39.5 mm for wire cases (range, 12-90). Time from incision to specimen radiograph was shorter in EMC compared with wire cases, but not statistically significant. Cases with EMC had a fewer number of positive/close (<2 mm) ductal carcinoma in situ margins (29%), compared with 50% of the wire localized cases (P <.072). Specimen length and volume were also significantly lower with EMC vs wire localization (P = .029 and P = .019, respectively). Also, 93.5% of patients who underwent EMC localization had complete retrieval of localization device in the initial specimen (P = .172). Reoperation reexcision of tumor margins was required for only 29% of the EMC localized patients (P = .185). Use of the EMC localizer was also associated with a lower complication rate (6.5% vs. 9.3%; P = 1.00).

Conclusion

In this prospective, single-institution study, EMC localization was associated with fewer positive margins and smaller resection specimens in EMC bracketed BCS compared with wire bracketed procedures.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content